Johnson & Johnson Announces Completion of Synthes Acquisition
Johnson & Johnson announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock. Synthes will now be integrated with the DePuy franchise to establish the DePuy Synthes Companies of Johnson & Johnson.
Under the terms of the agreement, each share of Synthes common stock will be exchanged for CHF 55.65 in cash and 1.7170 shares of Johnson & Johnson common stock. Cash will be provided for fractional shares.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Monsanto Executive Vice President and Chief Financial Officer Terry Crews to Retire - Carl Casale, Executive Vice President, Strategy and Operations, To Succeed Crews as CFO

Precise Decoding of Breast Cancer Cells Creates New Option for Treatment
BIO White Paper Dispels Over-Patenting Myth - Patenting is a Critical Element in Fostering Research and Development
Acacia Pharma initiates phase IIa clinical trial with APD421 for nausea and vomiting
Anti-anxiety Compound BNC210 Phase I Trial Successful: Establishes Four-fold Increase in Blood Drug Levels Following Food Intake
Biotest opens new plasma collection centre in Vermillion, South Dakota
Epigenetic analysis of aggressive brain tumors
